Your browser doesn't support javascript.
loading
Somatic structural variants drive distinct modes of oncogenesis in melanoma.
Conway, Jake R; Gillani, Riaz; Crowdis, Jett; Reardon, Brendan; Park, Jihye; Han, Seunghun; Titchen, Breanna; Benamar, Mouadh; Haq, Rizwan; Van Allen, Eliezer M.
Affiliation
  • Conway JR; Division of Medical Sciences, Harvard University, Boston, Massachusetts, USA.
  • Gillani R; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Crowdis J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Reardon B; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Park J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Han S; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
  • Titchen B; Boston Children's Hospital, Boston, Massachusetts, USA.
  • Benamar M; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Haq R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Van Allen EM; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
J Clin Invest ; 134(13)2024 May 14.
Article in En | MEDLINE | ID: mdl-38758740
ABSTRACT
The diversity of structural variants (SVs) in melanoma and how they impact oncogenesis are incompletely known. We performed harmonized analysis of SVs across melanoma histologic and genomic subtypes, and we identified distinct global properties between subtypes. These included the frequency and size of SVs and SV classes, their relation to chromothripsis events, and the impact on cancer-related genes of SVs that alter topologically associated domain (TAD) boundaries. Following our prior identification of double-stranded break repair deficiency in a subset of triple-wild-type cutaneous melanoma, we identified MRE11 and NBN loss-of-function SVs in melanomas with this mutational signature. Experimental knockouts of MRE11 and NBN, followed by olaparib cell viability assays in melanoma cells, indicated that dysregulation of each of these genes may cause sensitivity to PARP inhibitors in cutaneous melanomas. Broadly, harmonized analysis of melanoma SVs revealed distinct global genomic properties and molecular drivers, which may have biological and therapeutic impact.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanoma Limits: Humans Language: En Journal: J Clin Invest Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanoma Limits: Humans Language: En Journal: J Clin Invest Year: 2024 Document type: Article